查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2135503

泌尿器官系統抗生素市場：全球市場預測，2026-2032年

Urinary System Antibiotics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，泌尿器官系統抗生素市場將成長至 6.8547 億美元，複合年成長率為 7.85%。

主要市場統計數據
基準年 2025 4.0386億美元
預計年份：2026年 4.4025億美元
預測年份 2032 6.8547億美元
複合年成長率 (%) 7.85%

泌尿器官系統抗生素：概述

泌尿器官系統抗生素是指用於治療膀胱、腎臟、尿道及相關泌尿系統結構的細菌感染疾病的藥物。其臨床意義取決於感染疾病的嚴重程度、是否復發、患者的年齡、懷孕狀況、腎功能、醫療資源的可近性以及當地的抗生素抗藥性模式。在製定治療策略時，診斷確認、合理用藥管理和安全性考慮的重要性日益凸顯，而不再僅依賴常規的經驗性用藥。

抗生素抗藥性正在改變治療途徑。

治療方法正從基於常規方案的廣泛處方轉向基於尿液培養、藥敏試驗和區域監測的標靶治療。復發性行為感染、醫療相關感染疾病、複雜性尿道感染以及抗藥性革蘭氏陰性菌感染疾病進一步增加了治療的複雜性。因此，醫院和門診診所正致力於加強抗生素使用管理、最佳化臨床路徑、確保並重新評估患者的用藥依從性，以及預防不必要的抗生素暴露。

人工智慧有助於更快、更準確地做出決策。

人工智慧 (AI) 可以幫助臨床醫生解讀檢測結果，識別抗藥性感染疾病高風險患者，輔助選擇抗生素，並發現需要審查的處方模式。它還可以支援醫療保健系統內的監測，最佳化診斷流程，並預測後續追蹤的必要性。有效利用人工智慧需要代表性的臨床數據、透明的檢驗、隱私保護、互通性以及臨床醫生的監督。人工智慧應補充而非取代微生物學知識和醫學判斷。

地區差異反映了容忍度、獲取途徑以及管理和維護正確使用的能力。

在北美，儘管先進的診斷技術和合理使用抗生素的基礎設施已相當完善，但尿道感染感染的抗生素抗藥性和醫療保健體系碎片化問題仍然令人擔憂。在拉丁美洲，檢測服務普及程度參差不齊，處方習慣各異，監測能力也存在區域差異。在歐洲，協調合理的抗生素使用、實驗室治療和跨境監測仍然至關重要。在中東，各國的醫療保健體系和抗生素抗藥性狀況不盡相同；而在非洲，診斷工具的可用性、藥物取得途徑以及監測不足都產生了顯著影響。在亞太地區，醫療體係高度發達，而一些地區則亟需加強對非處方藥取得、抗生素使用和檢測能力的監管，兩者之間存在著巨大的差異。

經濟與安全集團負責制定政策協調。

東南亞國協醫療衛生系統能力雖有差異，但均受益於通用的監測和合理用藥方法。金磚國家成員國的抗藥性環境各不相同，可以為合作研究、強化檢測系統和負責任的採購慣例做出貢獻。歐盟支持協調一致的監測和跨境公共衛生措施。七國集團成員國在調查、診斷和合理用藥管理方面普遍實力雄厚，但仍需持續應對抗藥性感染疾病，並確保門診病人的合理用藥。海灣合作理事會成員國有能力促進醫院綜合監測和診斷服務的普及，而北約成員國則必須將抗菌素抗藥性問題納入更廣泛的健康安全保障計畫中。

成熟系統和新興系統因國家而異，其優先事項也不同。

澳洲優先考慮合理用藥、監測和循證處方箋。巴西和墨西哥持續在保障藥品可及性、應對抗菌素抗藥性和加強診斷系統之間尋求平衡。加拿大、美國、英國、德國、義大利和西班牙擁有完善的臨床和實驗室基礎設施，其當前優先事項包括減少不合理用藥、控制抗藥性感染疾病以及加強門診和住院治療之間的協調。中國和印度致力於在其龐大且多元化的醫療保健系統中推廣合理用藥、診斷和監測。日本和韓國在維持先進醫療服務能力的同時，也持續關注人口老化、復發性行為感染和抗菌素抗藥性管理等議題。俄羅斯需要確保可靠的監測、合理的處方以及持續獲得高品質的診斷和藥物。

優先考慮診斷、管理和以患者為中心的就醫途徑。

產業領導者必須使其產品開發和服務策略與已證實的臨床需求、本地藥物敏感性數據和負責任用藥原則保持一致。優先事項包括支持快速且經濟的診斷、加強對處方醫生和患者的教育、改善藥物依從性訊息，以及為復發性和複雜感染疾病制定循證治療方案。各機構也應投資於藥物安全監測、真實世界結果研究、可互通的數據系統，以及與實驗室和公共衛生機構的合作。在使用人工智慧時，必須納入前瞻性檢驗、偏差監測、網路安全措施和明確的課責。

利用數據驅動調查方法撰寫執行摘要。

本概要整合了泌尿器官系統抗生素的既定應用範圍，並結合了已建立的臨床、公共衛生和合理抗菌藥物使用原則。分析內容涵蓋治療趨勢、抗藥性動態、數位化和人工智慧應用、區域背景、經濟和安全分類以及具體國家。所有解讀均為定性分析，且有意排除市場規模估算、市場佔有率、預測以及公司特定評估。在做出任何實際決策之前，應參考現行指南、監測報告、監管文件和同儕審查證據對結論進行檢驗。

合理使用抗生素是一項核心策略挑戰。

目前泌尿器官系統抗生素的現況取決於如何在確保及時治療細菌感染疾病患者的同時，維持其療效。抗藥性監測、便利的診斷、協作式合理用藥管理以及精心管理的數位化工具是區域和國家層面最重要的通用優先事項。能夠將臨床證據與公平取得、安全監測和課責的創新相結合的領導者，將更有能力支持患者和公眾健康的永續發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章泌尿器官系統抗生素市場：依給藥途徑分類

  • 靜脈
  • 口服

第8章泌尿器官系統抗生素市場：依適應症分類

  • 預防
  • 治療
    • 急性單純性尿道感染
    • 複雜性尿道感染
      • 膀胱炎
      • 腎盂腎炎

第9章泌尿器官系統抗生素市場：以劑型分類

  • 膠囊
  • 注射藥物
  • 口服懸浮液
  • 藥片

第10章泌尿器官系統抗生素市場：依藥物類別分類

  • BETA-內醯胺
    • 碳青黴烯類
    • 頭孢菌素
      • 第一代
      • 第四代
      • 第二代
      • 第三代
    • 青黴素類
  • Fluoroquinolones
  • 硝基呋喃
  • 膦酸衍生物
  • 磺胺類藥物

第11章泌尿器官系統抗生素市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章泌尿器官系統抗生素市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章泌尿器官系統抗生素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章泌尿器官系統抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Healthcare Ltd
  • Cipla Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc
  • Sandoz AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc

第17章 主要專家

Product Code: MRR-961F26FD6487

The Urinary System Antibiotics Market is projected to grow by USD 685.47 million at a CAGR of 7.85% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 403.86 million
Estimated Year [2026] USD 440.25 million
Forecast Year [2032] USD 685.47 million
CAGR (%) 7.85%

Urinary System Antibiotics: Executive Overview

Urinary system antibiotics encompass medicines used to treat bacterial infections affecting the bladder, kidneys, urethra, and related urinary structures. Their clinical importance is shaped by infection severity, recurrence, patient age, pregnancy status, kidney function, healthcare access, and local antimicrobial-resistance patterns. Treatment decisions increasingly require diagnostic confirmation, stewardship, and attention to safety rather than routine empiric prescribing alone.

Antimicrobial Resistance Is Reshaping Treatment Pathways

The landscape is shifting from broad, protocol-driven prescribing toward targeted therapy supported by urine culture, susceptibility testing, and local surveillance. Recurrent infections, healthcare-associated infections, complicated urinary tract infections, and infections caused by resistant Gram-negative organisms create greater therapeutic complexity. Hospitals and outpatient providers are therefore strengthening stewardship programs, refining clinical pathways, and emphasizing adherence, reassessment, and prevention of avoidable antibiotic exposure.

Artificial Intelligence Supports Faster, More Precise Decisions

Artificial intelligence can help clinicians interpret laboratory results, identify patients at elevated risk of resistant infection, support antimicrobial selection, and detect prescribing patterns that warrant review. It can also assist health systems with surveillance, diagnostic workflow prioritization, and prediction of follow-up needs. Effective deployment depends on representative clinical data, transparent validation, privacy safeguards, interoperability, and clinician oversight; AI should complement microbiology and medical judgment rather than replace them.

Regional Differences Reflect Resistance, Access, and Stewardship Capacity

North America combines advanced diagnostics and stewardship infrastructure with substantial concern about resistant urinary pathogens and care fragmentation. Latin America faces uneven access to testing, variable prescribing practices, and differing surveillance capacity. Europe continues to emphasize coordinated stewardship, laboratory-guided treatment, and cross-border monitoring. The Middle East shows diverse healthcare capabilities and resistance profiles across countries, while Africa is strongly influenced by diagnostic availability, medicine access, and surveillance gaps. Asia-Pacific presents wide variation, ranging from highly developed health systems to settings where over-the-counter access, antibiotic use, and laboratory capacity require stronger oversight.

Economic and Security Groups Shape Policy Coordination

ASEAN countries face varied health-system capacity and benefit from shared surveillance and stewardship approaches. BRICS members span diverse resistance environments and can contribute to collaborative research, laboratory strengthening, and responsible procurement practices. The European Union supports coordinated monitoring and cross-border public-health action. G7 members generally have strong research, diagnostic, and stewardship capabilities but continue to address resistant infections and appropriate outpatient use. GCC states are positioned to advance integrated hospital surveillance and diagnostic access, while NATO members must consider antimicrobial resilience as part of broader health-security preparedness.

Country-Level Priorities Vary Across Established and Emerging Systems

Australia emphasizes stewardship, surveillance, and evidence-based prescribing. Brazil and Mexico continue to balance access with resistance control and diagnostic strengthening. Canada, the United States, the United Kingdom, France, Germany, Italy, and Spain have substantial clinical and laboratory infrastructure, while ongoing priorities include reducing inappropriate use, managing resistant infections, and improving continuity between outpatient and hospital care. China and India are focused on expanding stewardship, diagnostics, and surveillance across large and diverse health systems. Japan and South Korea combine advanced care capabilities with continued attention to aging populations, recurrent infections, and resistance management. Russia faces the need for reliable surveillance, appropriate prescribing, and consistent access to quality diagnostics and medicines.

Prioritize Diagnostics, Stewardship, and Patient-Centered Access

Industry leaders should align product development and service strategies with documented clinical needs, local susceptibility data, and responsible-use principles. Priorities include supporting rapid and affordable diagnostics, strengthening education for prescribers and patients, improving adherence information, and developing evidence-based pathways for recurrent and complicated infections. Organizations should also invest in pharmacovigilance, real-world outcomes research, interoperable data systems, and partnerships with laboratories and public-health agencies. Any use of AI should include prospective validation, bias monitoring, cybersecurity controls, and clear accountability.

Methodology for a Data-Grounded Executive Summary

This summary synthesizes the defined urinary system antibiotics scope with established clinical, public-health, and antimicrobial-stewardship considerations. The analysis is organized across treatment trends, resistance dynamics, digital and AI applications, regional environments, economic and security groupings, and specified countries. Interpretations are qualitative and deliberately exclude market estimates, sizing, shares, forecasts, and company-specific assessments. Conclusions should be validated against current guidelines, surveillance reports, regulatory materials, and peer-reviewed evidence before operational decisions are made.

Responsible Antibiotic Use Is the Central Strategic Imperative

The urinary system antibiotics landscape is being defined by the need to preserve effectiveness while ensuring timely treatment for patients with bacterial infection. Resistance surveillance, accessible diagnostics, coordinated stewardship, and carefully governed digital tools are the strongest common priorities across regions and country groups. Leaders that connect clinical evidence with equitable access, safety monitoring, and accountable innovation will be better positioned to support durable patient and public-health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary System Antibiotics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral

8. Urinary System Antibiotics Market, by Indication

  • 8.1. Introduction
  • 8.2. Prophylaxis
  • 8.3. Treatment
    • 8.3.1. Acute Uncomplicated Uti
    • 8.3.2. Complicated Uti
      • 8.3.2.1. Cystitis
      • 8.3.2.2. Pyelonephritis

9. Urinary System Antibiotics Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Capsule
  • 9.3. Injection
  • 9.4. Oral Suspension
  • 9.5. Tablet

10. Urinary System Antibiotics Market, by Drug Class

  • 10.1. Introduction
  • 10.2. Beta-Lactams
    • 10.2.1. Carbapenems
    • 10.2.2. Cephalosporins
      • 10.2.2.1. First Generation
      • 10.2.2.2. Fourth Generation
      • 10.2.2.3. Second Generation
      • 10.2.2.4. Third Generation
    • 10.2.3. Penicillins
  • 10.3. Fluoroquinolones
  • 10.4. Nitrofurans
  • 10.5. Phosphonic Acid Derivatives
  • 10.6. Sulfonamides

11. Urinary System Antibiotics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Urinary System Antibiotics Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Urinary System Antibiotics Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Urinary System Antibiotics Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AstraZeneca plc
  • 16.3. Aurobindo Pharma Limited
  • 16.4. Bayer AG
  • 16.5. Cadila Healthcare Ltd
  • 16.6. Cipla Limited
  • 16.7. GlaxoSmithKline plc
  • 16.8. Johnson & Johnson
  • 16.9. Lupin Limited
  • 16.10. Merck & Co., Inc
  • 16.11. Novartis AG
  • 16.12. Pfizer Inc
  • 16.13. Sandoz AG
  • 16.14. Sanofi S.A
  • 16.15. Teva Pharmaceutical Industries Ltd
  • 16.16. Viatris Inc

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Urinary System Antibiotics Market, Years Considered for the Study
  • FIGURE 2. Global Urinary System Antibiotics Market, Research Design
  • FIGURE 3. Global Urinary System Antibiotics Market, Research Framework
  • FIGURE 4. Global Urinary System Antibiotics Market, Data Triangulation
  • FIGURE 5. Global Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Urinary System Antibiotics Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 7. Global Urinary System Antibiotics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Urinary System Antibiotics Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global Urinary System Antibiotics Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Urinary System Antibiotics Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global Urinary System Antibiotics Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Urinary System Antibiotics Market Size, by Drug Class, 2025 vs 2032 (%)
  • FIGURE 13. Global Urinary System Antibiotics Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Urinary System Antibiotics Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 15. Global Urinary System Antibiotics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Urinary System Antibiotics Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Urinary System Antibiotics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Urinary System Antibiotics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Urinary System Antibiotics Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Urinary System Antibiotics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Urinary System Antibiotics Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Urinary System Antibiotics Market Segmentation & Coverage
  • TABLE 2. Global Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 4. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 11. Global Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Treatment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Treatment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Treatment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Acute Uncomplicated Uti Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Acute Uncomplicated Uti Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Acute Uncomplicated Uti Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Complicated Uti Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Complicated Uti Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Complicated Uti Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Cystitis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Cystitis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Cystitis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Pyelonephritis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Pyelonephritis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Pyelonephritis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 30. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 43. Global Beta-Lactams Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Beta-Lactams Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Beta-Lactams Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Carbapenems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Carbapenems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Carbapenems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Cephalosporins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Cephalosporins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Cephalosporins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global First Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global First Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global First Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Fourth Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Fourth Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Fourth Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Second Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Second Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Second Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Third Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Third Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Third Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Penicillins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Penicillins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Penicillins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Fluoroquinolones Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Fluoroquinolones Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Fluoroquinolones Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Nitrofurans Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Nitrofurans Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Nitrofurans Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Phosphonic Acid Derivatives Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Phosphonic Acid Derivatives Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Phosphonic Acid Derivatives Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Sulfonamides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Sulfonamides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Sulfonamides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 80. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 98. Asia-Pacific Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 100. North America Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. North America Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 102. North America Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 103. North America Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 104. North America Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 105. North America Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 106. North America Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 107. North America Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 108. North America Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 109. North America Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 110. Latin America Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Latin America Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 112. Latin America Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 113. Latin America Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 114. Latin America Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 115. Latin America Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 116. Latin America Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 117. Latin America Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 118. Latin America Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 119. Latin America Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 120. Europe Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Europe Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 122. Europe Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 123. Europe Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 124. Europe Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 125. Europe Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 126. Europe Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 127. Europe Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 128. Europe Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 129. Europe Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 130. Middle East Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 131. Middle East Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 132. Middle East Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 133. Middle East Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 134. Middle East Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 135. Middle East Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 136. Middle East Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 137. Middle East Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 138. Middle East Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 139. Middle East Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 140. Africa Urinary System Antibiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 141. Africa Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 142. Africa Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 143. Africa Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 144. Africa Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 145. Africa Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 146. Africa Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 147. Africa Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 148. Africa Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 149. Africa Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 150. Global Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. ASEAN Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 152. ASEAN Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. ASEAN Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 154. ASEAN Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 155. ASEAN Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 156. ASEAN Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 157. ASEAN Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 158. ASEAN Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 159. ASEAN Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 160. ASEAN Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. GCC Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 162. GCC Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 163. GCC Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. GCC Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 165. GCC Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 166. GCC Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 167. GCC Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 168. GCC Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 169. GCC Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 170. GCC Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 171. European Union Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 172. European Union Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 173. European Union Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 174. European Union Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 175. European Union Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 176. European Union Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 177. European Union Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 178. European Union Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 179. European Union Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 180. European Union Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 181. BRICS Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 182. BRICS Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 183. BRICS Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 184. BRICS Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 185. BRICS Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 186. BRICS Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 187. BRICS Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 188. BRICS Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 189. BRICS Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 190. BRICS Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. G7 Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. G7 Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 193. G7 Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 194. G7 Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 195. G7 Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 196. G7 Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 197. G7 Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 198. G7 Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 199. G7 Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 200. G7 Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 201. NATO Urinary System Antibiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 202. NATO Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 203. NATO Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 204. NATO Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 205. NATO Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 206. NATO Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 207. NATO Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 208. NATO Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 209. NATO Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 210. NATO Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 211. Global Urinary System Antibiotics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 212. United States Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 213. United States Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 214. United States Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 215. United States Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 216. United States Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 217. United States Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 218. United States Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 219. United States Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 220. United States Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 221. United States Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 222. Canada Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 223. Canada Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 224. Canada Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 225. Canada Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 226. Canada Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 227. Canada Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 228. Canada Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 229. Canada Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 230. Canada Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 231. Canada Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 232. Mexico Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 233. Mexico Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 234. Mexico Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 235. Mexico Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 236. Mexico Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 237. Mexico Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 238. Mexico Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 239. Mexico Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 240. Mexico Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 241. Mexico Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 242. Brazil Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 243. Brazil Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. Brazil Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 245. Brazil Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 246. Brazil Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 247. Brazil Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 248. Brazil Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 249. Brazil Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 250. Brazil Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 251. Brazil Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 252. United Kingdom Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 253. United Kingdom Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 254. United Kingdom Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 255. United Kingdom Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 256. United Kingdom Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 257. United Kingdom Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 258. United Kingdom Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 259. United Kingdom Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 260. United Kingdom Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 261. United Kingdom Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 262. Germany Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 263. Germany Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 264. Germany Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 265. Germany Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 266. Germany Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 267. Germany Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 268. Germany Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 269. Germany Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 270. Germany Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 271. Germany Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 272. France Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 273. France Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 274. France Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 275. France Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 276. France Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 277. France Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 278. France Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 279. France Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 280. France Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 281. France Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 282. Russia Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 283. Russia Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 284. Russia Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 285. Russia Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 286. Russia Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 287. Russia Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 288. Russia Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 289. Russia Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 290. Russia Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 291. Russia Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 292. Italy Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 293. Italy Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 294. Italy Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 295. Italy Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 296. Italy Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 297. Italy Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 298. Italy Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 299. Italy Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 300. Italy Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 301. Italy Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 302. Spain Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 303. Spain Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 304. Spain Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 305. Spain Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 306. Spain Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 307. Spain Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 308. Spain Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 309. Spain Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 310. Spain Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 311. Spain Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 312. China Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 313. China Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 314. China Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 315. China Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 316. China Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 317. China Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 318. China Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 319. China Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 320. China Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 321. China Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 322. India Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 323. India Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 324. India Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 325. India Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 326. India Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 327. India Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 328. India Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 329. India Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 330. India Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 331. India Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 332. Japan Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 333. Japan Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 334. Japan Urinary System Antibiotics Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 335. Japan Urinary System Antibiotics Market Size, by Treatment, 2017-2032 (USD Million)
  • TABLE 336. Japan Urinary System Antibiotics Market Size, by Complicated Uti, 2017-2032 (USD Million)
  • TABLE 337. Japan Urinary System Antibiotics Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 338. Japan Urinary System Antibiotics Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 339. Japan Urinary System Antibiotics Market Size, by Beta-Lactams, 2017-2032 (USD Million)
  • TABLE 340. Japan Urinary System Antibiotics Market Size, by Cephalosporins, 2017-2032 (USD Million)
  • TABLE 341. Japan Urinary System Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 342. Australia Urinary System Antibiotics Market Size, 2017-2032 (USD Million)
  • TABLE 343. Australia Urinary System Antibiotics Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 344. Australia Urinary System Antibiot